泽璟制药(688266.SH)业绩快报：2025年净亏损1.61亿元

Core Viewpoint - Zejing Pharmaceutical (688266.SH) reported a significant increase in revenue for the fiscal year 2025, but also experienced a larger net loss compared to the previous year [1] Financial Performance - The company achieved an operating revenue of 813 million yuan, representing a year-on-year growth of 52.50% [1] - The net profit attributable to shareholders was -161 million yuan, with a net profit excluding non-recurring gains and losses of -212 million yuan, indicating an increase in losses compared to the previous year [1] - The weighted average return on net assets was -13.76%, with losses increasing by 4.34 percentage points year-on-year [1] Product Development and Market Expansion - The company successfully launched Jikaxitini tablets, focusing on market expansion to enhance the drug's market coverage [1] - The recombinant human thrombin was officially included in the national medical insurance directory, leading to a rapid increase in the number of hospitals and sales through collaboration with exclusive marketing partners [1] - The company continued to advance new drug research and development, resulting in an increase in R&D expenses year-on-year due to varying stages of development for different projects [1]